Published in World J Hepatol on July 28, 2015
New imaging techniques for liver diseases. J Hepatol (2014) 2.25
Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol (2009) 1.89
Dual-source parallel radiofrequency excitation body MR imaging compared with standard MR imaging at 3.0 T: initial clinical experience. Radiology (2010) 1.54
A review of MR physics: 3T versus 1.5T. Magn Reson Imaging Clin N Am (2007) 1.37
Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging (2011) 1.34
Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat content. J Magn Reson Imaging (2009) 1.25
Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol (2010) 1.10
Quantitative proton magnetic resonance spectroscopy of the normal liver and malignant hepatic lesions at 3.0 Tesla. Eur Radiol (2008) 1.09
3.0-T MR imaging of the abdomen: comparison with 1.5 T. Radiographics (2008) 1.07
Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol (2013) 1.07
Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol (2010) 1.01
Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla. Eur Radiol (2014) 1.00
Liver MR imaging: 1.5T versus 3T. Magn Reson Imaging Clin N Am (2007) 0.98
Focal liver lesions at 3.0 T: lesion detectability and image quality with T2-weighted imaging by using conventional and dual-source parallel radiofrequency transmission. Radiology (2011) 0.94
Comparison of gadoxetic acid-enhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases. J Magn Reson Imaging (2011) 0.92
Diffusion-weighted imaging of the abdomen at 3 T: image quality comparison with 1.5-T magnet using 3 different imaging sequences. J Comput Assist Tomogr (2011) 0.90
Abdominal magnetic resonance imaging at 3.0 T what is the ultimate gain in signal-to-noise ratio? Acad Radiol (2006) 0.88
Abdominal MR imaging at 3.0 T. Radiographics (2007) 0.88
High-field-strength MR imaging of the liver at 3.0 T: intraindividual comparative study with MR imaging at 1.5 T. Radiology (2006) 0.88
Superparamagnetic iron oxide-enhanced liver magnetic resonance imaging: comparison of 1.5 T and 3.0 T imaging for detection of focal malignant liver lesions. Invest Radiol (2006) 0.84
Hepatic Iron Quantification on 3 Tesla (3 T) Magnetic Resonance (MR): Technical Challenges and Solutions. Radiol Res Pract (2013) 0.84
Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. Eur J Surg Oncol (2012) 0.82
Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient. J Magn Reson Imaging (2012) 0.81
Is water diffusion isotropic in the cirrhotic liver? a study with diffusion-weighted imaging at 3.0 Tesla. Acad Radiol (2011) 0.81
Comparison of breathhold, navigator-triggered, and free-breathing diffusion-weighted MRI for focal hepatic lesions. J Magn Reson Imaging (2012) 0.80
Quantitative and qualitative comparison of 0.025 mmol/kg gadobenate dimeglumine for abdominal MRI at 1.5T and 3T MRI in patients with low estimated glomerular filtration rate. Eur J Radiol (2014) 0.80
3.0-T MRI evaluation of patients with chronic liver diseases: initial observations. Magn Reson Imaging (2008) 0.80
Gadoxetic acid-enhanced fat suppressed three-dimensional T1-weighted MRI using a multiecho dixon technique at 3 tesla: emphasis on image quality and hepatocellular carcinoma detection. J Magn Reson Imaging (2013) 0.80
Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations. AJR Am J Roentgenol (2011) 0.79
Quantitative and qualitative comparison of 1.5 and 3.0 Tesla MRI in patients with chronic liver diseases. J Magn Reson Imaging (2009) 0.79
Value of 3 Tesla diffusion-weighted magnetic resonance imaging for assessing liver fibrosis. Ann Gastroenterol (2015) 0.77
Quantitative and qualitative comparison of 3.0T and 1.5T MR imaging of the liver in patients with diffuse parenchymal liver disease. Eur J Radiol (2008) 0.77
Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma? PLoS One (2014) 0.77
Liver MRI at 3.0 tesla: comparison of image quality and lesion detectability between single-source conventional and dual-source parallel radiofrequency transmissions. J Comput Assist Tomogr (2012) 0.76